Atea Pharmaceuticals, Inc. (AVIR) delivered a return of 32.54% over the past year. Since AVIR does not currently pay dividends, the total return equals the price-only return.

A $10,000 investment in Atea Pharmaceuticals, Inc. one year ago would be worth $13,254 today, representing a gain of $3,254.

Atea Pharmaceuticals, Inc. (AVIR) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For AVIR, the total return equals the price-only return.

Yes, Atea Pharmaceuticals, Inc. (AVIR) outperformed the S&P 500 by 11.70 percentage points over the past year. AVIR delivered a total return of 32.54%, compared to the S&P 500's 20.84%. This 11.70pp alpha means investors in AVIR earned more than a passive S&P 500 index fund.

Atea Pharmaceuticals, Inc. (AVIR) experienced a maximum drawdown of -33.33% over the past year, declining from its peak on 2026-03-09 to its trough on 2026-05-15. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Here are Atea Pharmaceuticals, Inc. (AVIR)'s long-term returns with dividends reinvested. Over 10 years, the total return is -85.2% (-17.4% CAGR) — $10,000 would have grown to $1,477. Over 20 years: -85.2% total return (-9.1% CAGR) — $10,000 → $1,477. Over 30 years: -85.2% total return (-6.2% CAGR) — $10,000 → $1,477. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Atea Pharmaceuticals, Inc.'s best calendar year was 2020 with a total return of 37.7%. Its worst year was 2021 with a total return of -78.4%. This range shows the volatility investors should expect — the difference between the best and worst year is 116.1 percentage points.